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Background: Endothelial dysfunction is a well documented evidence for the onset of atherosclerosis and other
cardiovascular diseases. Lipids disorder is among the main risk factors for endothelial dysfunction in these diseases.
Steroidogenic acute regulatory protein (StAR), one of the cholesterol transporters, plays an important role in the
maintenance of intracellular lipid homeostasis. However, the effect of StAR on endothelial dysfunction is not well
understood. Palmitic acid (PA) has been shown to decrease eNOS activity and induce inflammation, both are the
causes of endothelial dysfunction, in an endothelial cell culture model.
Methods: StAR gene was introduced into primary rat aortic endothelial cells by adenovirus infection. Real-time PCR
and Western blotting were performed to determine the relative genes and proteins expression level to elucidate
the underlying mechanism. The free fatty acid and cholesterol quantification kits were used to detect total cellular
free fatty acid and cholesterol. The levels of inflammatory factors and nitric oxide were determined by ELISA and
classic Griess reagent methods respectively.
Results: We successfully overexpressed StAR in primary rat aortic endothelial cells. Following StAR overexpression,
mRNA levels of IL-1β, TNFα, IL6 and VCAM-1 and protein levels of IL-1β, , TNFα and IL-6 in culture supernatant
were significantly decreased, which duing to blocke NFκB nuclear translocation and activation. Moreover, StAR
overexpression attenuated the PA-induced reduction of nitric oxide bioavailability by protecting the bioactivity of
pAkt/peNOS/NO pathway. Furthermore, the key genes involved in lipid metabolism were greatly reduced following
StAR overexpression. In order to investigate the underlying mechanism, cerulenin and lovastatin, the inhibitor of
fatty acid and cholesterol synthase, were added prior to PA treatment. The results showed that both cerulenin and
lovastatin had a similar effect as StAR overexpression. On the other hand, the role of StAR was inhibited when
siRNA was introduced to reduce StAR expression.
Conclusions: Our results showed that StAR attenuated lipid synthesis and uptake as well as PA-induced
inflammation and reduction in NO bioavailability in aortic endothelial cells. StAR can ameliorate endothelial
dysfunction induced by PA via reducing the intracellular lipid levels.
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The endothelium is considered to be the largest organ in
the body. It is strategically located between the wall of
blood vessels and the blood stream and is the major
regulator of vascular homeostasis. Endothelium main-
tains the balance between 1) vasodilation and vasocon-
striction, 2) inhibition and promotion of smooth muscle
cell proliferation and migration, 3) prevention and stimu-
lation of the adhesion and aggregation of platelets, and 4)
thrombogenesis and fibrinolysis [1]. When the latter
balance is disturbed, endothelial dysfunction occurs and
causes damage to the arterial wall [2]. The observations
made in human coronary arteries of atherosclerotic
patients suggest that endothelial dysfunction is an early
marker of atherosclerosis. The term “endothelial dys-
function” has been associated not only with atheroscler-
osis or hypertension, but also with other physiological
and pathophysiological process, including aging, coronary
syndrome, diabetes, impaired glucose tolerance, hyper-
glycemia, obesity, hypercholesterolemia, and inflammation
etc [3]. A better understanding of various physiological
and pathophysiological functions associated with endo-
thelial cells will eventually lead to not only a better
comprehension of these diseases but also improved pre-
ventive and therapeutic strategies.
Endothelial dysfunction is characterized by reduced
dilator function, increased inflammatory cell and platelet
adhesion, and increased coagulation activity [4]. Reduced
bioavailability of nitric oxide (NO) is a major contributor
of endothelial dysfunction [5]. Another potential trigger
for endothelial dysfunction is inflammation. Inflammatory
cytokines have been shown to impair endothelial func-
tion in animal models and isolated human veins [6].
Although there may be several drivers of endothelial
dysfunction, the accumulation of intracellular lipids in-
cluding triglycerides, cholesterol, and free fatty acid has
emerged as a key pathophysiological factor [7-9]. There-
fore, decreasing intracellular lipid levels in endothelial
cells may be the key step for preventing or reversing
endothelial dysfunction and related diseases, such as ath-
erosclerosis, insulin resistance, and metabolic syndrome.
Steroidogenic acute regulatory protein (StAR) is one
of the cholesterol transporters that initially found in
steroidogesis tissues. It transfers cholesterol from the
relatively cholesterol-rich outer mitochondrial membrane
to the cholesterol-poor inner mitochondrial membrane
for oxidation [10], which is the rate-limiting step in
steroidogenesis. Recently, StAR had been demonstrated
to be expressed in liver, endothelial cells other than the
steroidogenic tissue with similar function [11]. Previous
studies from our laboratory and others’ demonstrated
that StAR is also expressed in human monocytes, human
aorta [12], murine aorta [13], macrophages and endo-
thelial cells [14]. Overexpression of StAR increased themRNA and protein levels of ABCA1 and ABCG1 in
microvascular endothelial cells [15], and decreased the
cellular lipid levels and inflammation in macrophages
[16]. In vivo investigations showed that StAR over-
expression dramatically reduced cholesterol and triglycer-
ide levels in serum, liver and aorta [17]. These evidences
suggest that StAR plays a protective role in cardiovas-
cular disease. However, the role of StAR in endothelial
dysfunction remains unclear to date.
In the present study, the primary rat aortic endothelial
cells (RAECs) were treated with palmitic acid (PA) as
an in vitro model for endothelial dysfunction [18-20].
The effects of StAR overexpression on lipid metabolism,
inflammation and NO bioavailability were investigated
after infection with recombinant adenovirus encoding
StAR in RAECs. We show here that StAR overexpres-
sion decreases intracellular lipid levels by reducing
expression of genes involved in lipid metabolism. In
addition, StAR overexpression inhibited PA-induced in-
flammation and attenuated impairment of NO bioavil-
ability via regulating pAkt/peNOS/NO pathway. Overall
our findings provided a strong support for StAR being as
one of the key regulators for lipid metabolism and a pro-
tective molecule for endothelial dysfunctions in aortic
endothelium.Methods
Reagents
Culture media and reagents, fetal bovine serum, basic
fibroblast growth factor and TRIZOL reagent were
obtained from Invitrogen Life Technologies (Grand Island,
NY). RevertAld™ First Strand cDNA Synthesis Kit and
PageRuler Prestained Protein Ladder were purchased from
Fermentas MBI (San Diego, CA). SYBRW Green real-time
PCR Master Mix was from Bio-Rad (Hercules, CA). Pri-
mary antibodies against StAR, phosphor-eNOS (S1177)
and eNOS were purchased from Abcam Ltd (Cambridge
Science Park, Cambridge, UK). Antibodies against NF-κB
(p65) and Histone (H3) were purchased from Proteintech
Group, Inc (Chicago, IL). Phosphor-Akt (Ser473) was
from Cell Signaling Technology, Inc (Boston, MA). Akt
antibody was purchased from Bioworld technology, co,
Ltd (Nanjing, Jiangsu, China). Primary antibody against
b-actin and second antibodies against rabbit and mouse
IgG were obtained from CWbiotech (Beijing, China).
Cerulenin, an inhibitor of fatty acid synthase, was from
Biovision (Milpitas, CA). Lovastatin, an inhibitor of HMG-
CoA Reductase was purchased from Sigma-Aldrich Chem-
ical Co (St.Louis, MO). siRNA for StAR gene and negative
control were from Shanghai GenePharma., Ltd (Shanghai,
China). The recombinant adenovirus encoding StAR
(Ad-StAR) and the control adenovirus expressing the
enhanced green fluorescence protein (Ad-EGFP) was a
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Affairs Medical Center and Virginia Commonwealth
University, Richmond, VA). All other reagents were from
Sigma-Aldrich Chemical Co unless stated otherwise.Cell culture
Rat aortic endothelial cells (RAECs) were isolated and
cultured as described previously with minor modifica-
tions [21,22]. Briefly, segments of thoracic aorta were
excised from male Wistar rats (150-180 g) and immedi-
ately placed in cold PBS containing 100 U/ml penicillin
and 100 mg/ml streptomycin. The aorta was cut into
1 millimeter wide rings after the periadventitial fat was
removed. Following transferred to a T-25 cm2 flasks
(Nunc, Rochester, NY), the rings were cultured in
Medium 199 containing 20% fetal bovine serum, 2.5 ng/ml
basic fibroblast growth factors, 100U/ml penicillin and
100 mg/ml streptomycin. The aorta rings were placed at
37°C in a humidified atmosphere with 5% CO2 for 72-
80 h without movement. All pieces of aorta rings were
removed when cells migrated. Its microvascular cyto-
logical characteristics were demonstrated by CD31 and
vWF staining as shown in the previous study [21]. In
experiments involving PA treatment, M199 medium
supplemented with 1% bovine serum albumin was used.
All experiments were performed with RAECs up to
passage 4. In the experiments with inhibitor, 5 μg/ml
Cerulenin (in ethonal), or 5 μM lovastatin (in DMSO),
or 3.3 μg/ml cerulenin plus 3.3 μM lovastatin was
added in culture media 24 hours prior to PA treatment.
The same volume of solvents was added at the same time
as control. All experimental protocols were approved by
the Animals Care and Use Committee of Shanghai
Medical College, Fudan University which adopts the
guideline for the care and use of laboratory animals pub-
lished by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).Infection of cells with adenovirus encoding StAR
The RAECs were infected with recombinant adenovirus
encoding StAR (Ad-CMV-StAR) as previously described
[16,23]. Briefly, primary RAECs (4 × 105 cells/well) were
planted in 6-well plates (Costar, Corning, NY) in complete
culture medium. Twenty-four hours after planting, RAECs
were infected with recombinant adenovirus encoding
Ad-CMV-StAR at a multiplicity of 10, 20, 50 or 100 pfu/
cell. The recombinant adenovirus encoding enhanced
green fluorescence protein (Ad-CMV-EGFP) was used as
control. The virus was allowed to dwell for at least 2 h in
minimal culture medium with shaking every 15 minutes.
After 2 h of infection, unbound virus was removed and
replaced with fresh medium. The cells were incubated
for another 48 h before treatment. After determinationthe effect of infection, MOI = 10 were chose for the other
experiment with sufficient overexperssion and minimum
harm to the cells.Preparation of PA for vitro experiments
PA solution was prepared as described previously [24]
with minor modifications. In brief, stock PA (0.1 M) was
dissolved in 0.1 M NaOH at 70°C, and stored at -20°C.
PA preparation was thawed and mixed with serum- and
growth factor-free media in the presence of 1% BSA the
day before use.Supression of StAR with siRNA
To down-regulate StAR mRNA expression, we trans-
fected a siRNA specific for StAR and a non-coding
control siRNA (GenePharma Ltd, Shanghai, China) using
the Lipofectamine™ 2000 Transfection Reagent ( Invitro-
gen Life Technologies) according to the manufacturer’s
protocol. Twenty-four hours later, cells were treated with
PA and used for measuring gene expression (for inflam-
matory factor), and nitric oxide detection.Real-time quantitative PCR
To determine the effect of adenovirus infection, RAECs
were seeded in 6-well plates and infected with Ad-CMV-
StAR or Ad-CMV-EGFP for 48 h before harvest. To deter-
mine the effect of StAR overexperssion on the mRNA ex-
pression of inflammatory factors, RAECs were seeded in
6-well plates and treated with PA (200 μM) at different
time (0 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h) following with 48 h
infection. RAECs were lysed and total RNA was prepared
by TRIZOL reagent according to the manufacturer’s pro-
tocols. Complementary DNA (cDNA) was synthesized
from 2 mg total RNA by RevertAld™ First Strand cDNA
Synthesis Kit. Quantitative PCR was carried out in a
CFX96 Touch™ Real-Time PCR Detection System (Bio-
Rad, Hercules, CA) using SYBRW Green real-time PCR
Master Mix. Reaction contained 20 ng of cDNA and
0.25 μM forward and reverse primers were performed as
previously described [25]. The sequences of primers used
in this study were listed in Table 1.Western blotting
Cells were grown in either 100 mm dishes or 60 mm
dishes before lysis. To determine the transfection
effects of adenovirus, cells were harvested after 48 h
infection with different MOI adenovirus. To deter-
mine the effect of StAR overexperssion on pAkt/
peNOS/NO pathway, cells were lysed after treating
with 200 μM PA for 0, 30, 60 and 120 minutes fol-
lowing with 48 h infection. To determine the effect of
StAR overexperssion on nuclear translocation of
Table 1 The sequences of primers used in this experiment













Tian et al. Cardiovascular Diabetology 2012, 11:144 Page 4 of 12
http://www.cardiab.com/content/11/1/144NFκB (p65), cytosolic and nuclear fractions were iso-
lated and lysed after treating with 200 μM PA for 0,
15, 30, and 60 minutes following with 48 h infection.
Cytosolic and nuclear fractions were isolated with
Cytosolic and Nuclear Isolation Kit (Beyotime It. Co,
Nanjing, China). Lysate preparation and analysis was
done as previously described [16]. Fifty micrograms of
total protein and thirty micrograms of cytosolic and
nuclear was applied to SDS-PAGE gel electrophoresis
and transferred to PVDF membrane (Invitrogen,
Grand Island, NY) using a Bio-Rad transfer blottingFigure 1 StAR overexpression in RAECs by adenovirus infection. Prima
adenoviruses as described in the “Methods” section. StAR mRNA and prote
Western blotting analysis (B). A: Real-time quantitative PCR analysis of StAR
20, 50, 100) for 48 h. The data was normalized to internal GAPDH mRNA ex
StAR protein levels in RAECs after infection. β–actin serves as the loading c
represent the means ± S.D. from three independent experiments and show
represents cells infected with recombinant adenovirus encoding CMV-EGFP
adenovirus encoding CMV-StAR; * represents P < 0.05.system at 300 mA for 100 minutes. Proteins were
probed with the following antibodies overnight at 4°C:
StAR (1:2000), total Akt (1:1500), phospho-Akt Ser
473 (1:2000), total eNOS (1:1000), phospho-eNOS Ser
1177 (1:1000), and NFκB p65 (1:1500). To confirm
equal loading of the gels, membranes were reprobed
with β-actin (1:5000) for the whole lysates and
Histon-H3 (1:1500) for nuclear fractions. Semi-
quantitative analysis of protein expression was per-
formed by densitometry using NIH ImageJ software
(http://rsb.info.nih.gov/ij).ry cultured RAECs were infected with the indicated recombinant
in levels were determined by real-time Quantitative PCR (A) and
mRNA levels with adenovirus infection at different MOI (MOI = 10,
pression and presented as fold change. B: Western blotting analysis of
ontrol and a representative image is shown in upper panel. The data
n as fold change over the cells treated with Ad-CMV-EGFP. EGFP
and served as the negative control; StAR, cells infected with
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determination
After 48 h infection, cells were harvested in PBS and
lysated by sonication. Total intracellular cholesterol and
free fatty acid were extracted by homogenization with 1/2
volume of chloroform/isopropanol/NP-40 (7/11/0.1, v/v)
or chloroform-Triton X-100 (1% Triton X-100 in pure
chloroform), respectively. The organic phase (lower phase)
were collected and vacuumed dry to remove trace chloro-
form after spin the extracts at top speed in a microcentri-
fuge for 10 minutes. The extractions were redissolved and
detected by Free Fatty Acid and Cholesterol Quantifica-
tion Kit respectively (Applygen Technologies, Beijing,
China) according to the manufacturer’s instructions.ELISA assay for cytokines
RAECs were treated by PA (200 μM) overnight (16 h)
after 48 h infection and cell culture media were collected
to determine the effect of StAR overexpression on secre-
tion of cytokines. The cytokine levels (IL-1β, TNFα, and
IL-6) were determined by ELISA assay (NeoBioScience,
Shenzhen, China) following with the manufacturer’s
instructions.Figure 2 StAR overexpression inhibited expression of genes involved
acid and cholesterol. To determine the effect of StAR overexpression on
and intracellular total cholesterol and free fatty acid were detected after in
involved in lipid metabolism in RAECs infected with adenovirus. Data are p
levels). RAECs were infected with adenovirus as indicated, and intracellular
analyzed as described in the “Methods” section. Data represents the meansStatistic analysis
Data are presented as the mean ± S.D. Statistical ana-
lysis was performed using Student’s t test or ANOVA
as appropriate. P < 0.05 was considered statistically
significant.
Results
StAR overexpression in RAECs by adenovirus infection
StAR is a mitochondrial cholesterol transporter func-
tioning in the process of steroid hormones synthesis
[26]. Previous investigations have demonstrated that
StAR is also expressed in liver cells [11] and endothe-
lial cells [14]. However, our preliminary data showed
that StAR expression level is quite low in RAECs. To
investigate the effect of StAR on endothelial cells, we
overexpressed StAR using recombinant adenoviruses
carrying a CMV-driven gene encoding StAR (Ad-
CMV-StAR) in RAECs. After infection, RAECs pro-
duced both a high StAR mRNA and protein level
without inducing any cell toxicity. Real-time quantita-
tive PCR analysis showed that StAR mRNA level
increased by 708 to 6560 folds compared with the
Ad-EGFP group using different virus multiplicity of
infection (MOI) (Figure 1A). Western blotting analysisin lipid metabolism and reduced levels of intracellular free fatty
lipids metabolism, the gene expression involved in lipid metabolism
fected with adenovirus in RAECs. A: The mRNA levels of relative genes
resented as a ratio of gene-to-GAPDH expression (relative mRNA
total cholesterol (B) and free fatty acid (C) were extracted and
± S.D. from three independent experiments. * represents P < 0.05.
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lecular weight of 30 kD and a second 37 kD band
(Figure 1B) after infection, which is consistent with
StAR premature and mature proteins as shown in the
upper panel of Figure 1B. A summary of the data
normalized to β-actin is shown in the lower panel
(Figure 1B). Based on these results, we chose the
MOI = 10 in the subsequent experiments with ad-
equate overexpression effect and minimum toxicity.Figure 3 StAR overexpression reduced inflammatory factors expressio
were infected with Ad-CMV-EGFP or Ad-CMV-StAR at MOI = 10 for 48 h and
levels of IL-1β, TNFα, IL-6, VCAM-1 were analyzed by real-time quantitative
mRNA levels) and fold change over the relative mRNA levels at 0 h. (E thro
detected by ELISA. Data represents the means ± S.D. from three independeStAR overexpression inhibits expression of genes
involved in lipid metabolism and reduces levels of
intracellular free fatty acid and cholesterol
To determine whether StAR plays an important role in
endothelial lipid metabolism, we first employed real-
time quantitative PCR to analyze the expression of genes
involved in lipid metabolism in RAECs received Ad-
CMV-EGFP or Ad-CMV-StAR. Fourty-eight hours post
transduction, the relative mRNA levels of ACC-1, FAS,n and secretion after palmitic acid treatment in RAECs. RAECs
treated with PA (200 μM) in time-course. (A through D) The mRNA
PCR. Data represented as a ratio of gene-to-GAPDH expression (relative
ugh G) The contents of IL-1β, TNFα, IL-6 in culture supernatant were
nt experiments. * represents P < 0.05.
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63%, 62%, 87% and 81% respectively in the Ad-CMV-
StAR treated RAECs (Figure 2A), whereas the mRNA
levels of SREBP-1, CYP27A1, PPARa and PPARg did not
change significantly (data not shown). As demonstrated
in previous studies, ACC-1, FAS, HMGR, SREBP-2 and
LDLR are key enzymes involved in cholesterol and free
fatty acids (FFAs) synthesis and endocytosis [27-30].
Thus, we next extracted intracellular lipids as indicated
preciously [31]. Levels of cholesterol and FFAs were
determined 48 h post infection. As shown in Figure 2B
and C, intracellular total cholesterol and FFAs were
decreased by 53% and 29% respectively after StAR over-
expression compared with the Ad-CMV-EGFP group.StAR overexpression reduces inflammatory factors
expression and secretion after palmitic acid treatment
in RAECs
Numerous studies have shown that saturated FFAs could
readily induce inflammatory response in endothelial cells
via a NFκB-dependent pathway [32], and further cause
endothelial dysfunction. Based on our previous results,
we hypothesized that StAR plays a protective role in
endothelial dysfunction induced by FFA via regulating
lipid metabolism. Because palmitic acid (C16:0, PA) is a
major component of dietary saturated fat representing up
to 20% of the total FFA serum concentration [33], and has
been shown to be present in a high percentage of athero-
sclerotic lesion [19], we therefore used palmitic acid com-
bined with albumin to induce inflammation in RAECs.Figure 4 StAR overexpression inhibited PA-induced NFkB nuclear tran
in the nuclear extracts. B: Western blotting analysis of NFκB (p65) levels in
loading controls. Data represent the means ± S.D. for three independent ex
EGFP.To determine the role of StAR on inflammatory
responses induced by PA, adenovirus- transduced RAECs
were treated with PA (200 μM) in a time-dependent
manner. Cells were then harvested and total RNA was
extracted for mRNA analysis. Real-time quantitative PCR
analysis showed that the levels of IL-1β, TNFα, IL-6 and
VCAM-1 increased significantly in a time-dependent
manner after incubated with PA. At the same time, the
mRNA levels of IL-1β, TNFα, IL-6 and VCAM-1 in cells
with StAR overexpression were significantly lower than
those in cells transduced with Ad-CMV-EGFP at any
identical time (Figure 3, A-D).
To validate the changes in mRNA expression, culture
supernatant were collected after treated with PA for
16 h and ELISA analysis were performed. As shown in
Figure 3E, F and G, the contents of IL-1β, TNFα and
IL-6 were decreased by 24%, 21%, and 30% after StAR
overexpression.StAR overexpression inhibits PA-induced NFkB nuclear
translocation in RAECs
As shown in previous studies, the nuclear factor-κB
(NFκB) transcription factor family has been considered
the central mediator of the inflammatory process
[34,35]. Translocation from cytosol to nuclear of p65/
RelA, one of NFκB’s subunits, is the key step for NFκB
activation [36]. To further investigate the underlying
mechanism associated with StAR overexpression, we
examined the nuclear translocation of NFκB p65
(RelA), which is the critical step for NFκB activationslocation in RAECs. A: Western blotting analysis of NFκB (p65) levels
the cytosolic extracts. Histone H3 (HisH3) and β-actin were used as
periments and shown as densitometry analysis. * represents P < 0.05 vs.
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adenovirus infection, and total cytosolic and nuclear
proteins were extracted as described in the methods
section for western blotting analysis. As shown in
Figure 4A, the nuclear levels of NFkB p65 protein
were significantly increased after PA treatment. In con-
trast, the nuclear levels of NFκB p65 were reduced by
23% and 37% after StAR overexpression at 0.5 and 1 h
after PA treatment. Conversely, the cytosolic levels of
NFκB p65 were higher in cells with Ad-CMV-StAR in-
fection than those in cells received Ad-CMV-EGFP
(Figure 4B). These results suggested that StAR overex-
pression blocked PA-induced NFκB p65 nuclear trans-
location in RAECs and further inhibited transcription
of the inflammatory factors.Figure 5 StAR overexpression attenuated PA-induced reduction in NO
dependent manner after infected with adenovirus as indicated. The protein
and total eNOS were detected by Western blot. The NO content in media
blotting analysis of phosphor-Akt Ser 473 and total Akt. B: Western blotting
used as the loading control. Data represent the means ± S.D. from three in
Data represents the mean ± SE from three independent experiments. * reprStAR overexpression attenuates PA-induced reduction in
nitric oxide bioavailability
Excess PA has been shown to decrease eNOS activity
in an endothelial cell culture model [20], and impair
insulin-mediated NO production in human studies [38].
To investigate the effect of StAR overexpression on
PA-induced downregulation of pAkt/peNOS/NO path-
way, adenovirus-transduced RAECs were treated with
PA (200 μM) in a time-dependent manner, and the pro-
tein levels of phosphor-Akt Ser 473 (pAkt), total Akt,
phosphor-eNOS Ser 1177 (peNOS) and total eNOS were
examined by Western blotting. PA treatment impaired
the phosphorylation of Akt and eNOS in the absence of
obvious changes in total Akt or eNOS protein levels.
However, StAR overexpression attenuated the reductionbioavailability. RAECs were treated with PA (200 μM) in a time-
levels of phosphor-Akt Ser 473, total Akt, phosphor-eNOS Ser 1177
supernatant was detected by Nitric Oxide Detection Kit. A: Western
analysis of phosphor-eNOS Ser 1177 and total eNOS. β-actin was
dependent experiments. C: NO contents in the culture supernatant.
esents P < 0.05.
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groups (Figure 5A and B). Consistent with the levels of
eNOS phosphorylation/activation, NO bioavailability
was also repressed with PA treatment, and this effect was
partially blocked by StAR overexpression (Figure 5C).
siRNA specific for StAR has the reverse effect as StAR
overexpression on inflammatory factor mRNA expression
and NO production
As shown previously, StAR overexpression could attenuate
inflammatory response and NO production in RAECs
treated by PA. In order to confirm the role of StAR, we
performed the experiments with siRNA to knock-down
StAR expression prior to PA treatment. The results indi-
cated that StAR siRNA has the reverse effect as StARFigure 6 Cerulenin and lovastatin has the similar effect while StAR siR
inflammatory response and NO bioavailability. Before treated with PA (
or 5 μM lovastatin (in DMSO), or 3.3 μg/ml cerulenin plus 3.3 μM lovastatin
100 nM siRNA specific for StAR for 24 hours. The mRNA levels of IL-1β, TNF
NO content was detected by Nitric Oxide Detection Kit after PA treatment
analyzed by real-time quantitative PCR in cells pre-treated with indicial inh
by real-time quantitative PCR in cells pre-treated with siRNA specific for StA
transfection by real-time quantitative PCR. Data represented as a ratio of ge
control treatment mRNA levels at any indicial time. Data represents the me
culture supernatant. Data represents the mean ± SE from three independenoverexpression on mRNA expression of IL-1β, TNFα,
VCAM-1 and IL-6 and NO production (Figure 6B and C).Cerulenin, and lovastatin has the same effect as StAR
overexpression on inflammatory factor mRNA expression
and NO production
As shown in previous studies, StAR plays an important
role in lipid metabolism. To explore the underlying
mechanism of StAR’s protective effect on endothelial
dysfunction model, the inhibitor of fatty acid synthase
and HMG-CoA reductase, cerulenin and lovastatin, were
used before PA added. As shown in Figure 6A and C,
the mRNA expression of IL-1β, TNFα, VCAM-1 and
IL-6 were reduced while NO production was recoveredNA has the reverse effect as StAR overexpression in
200 μM), RAECs were treated with 5 μg/ml cerulenin (in ethonal),
for 24 hours. In another experiment, RAECs were transfected with
α, VCAM-1 and IL-6 were detected by real-time quantitative PCR and
for 2 hours. A. The mRNA levels of IL-1β, TNFα, VCAM-1, IL-6 were
ibitor. B. The mRNA levels of IL-1β, TNFα, VCAM-1, IL-6 were analyzed
R. Inset shows the confirmation of StAR mRNA reduction with siRNA
ne-to-GAPDH expression (relative mRNA levels) and ratio to the
ans ± S.D. from three independent experiments. C. NO contents in the
t experiments. * represents P < 0.05.
Tian et al. Cardiovascular Diabetology 2012, 11:144 Page 10 of 12
http://www.cardiab.com/content/11/1/144with inhibitor treatment. This experiment demonstrated
that the role of StAR on inflammatory response and
NO production might due to its regulatory role in
lipid metabolism. The schematic diagram was shown
in Figure 7 to indicate the pathway of StAR in endothe-
lial cells.Discussion
Vascular endothelial dysfunction is the initiation and
hallmark of various cardiovascular diseases, such as
atherosclerosis, hypertension, coronary vascular disease
and diabetes. Several therapeutic interventions, includ-
ing changes in lifestyle and pharmacologic treatments,
are used to ameliorate endothelial dysfunction under
various risk factors. It is of great interest to explore
new therapeutic strategies to improve endothelial func-
tion for protection and prevention of these diseases
which cause significant number of deaths each year.
In the present study, we provided insight into the ef-
fect of StAR on rat aortic endothelium lipid metabolism
and dysfunction. As shown in Figure 1, StAR mRNA
and protein levels were significantly increased by infec-
tion with recombinant adenovirus. Following StAR
overexpression, key genes involved in fatty acid synthe-
sis (FAS, ACC-1), cholesterol synthesis (HMGR) and
uptake (LDLR, SREBP-2) were greatly repressed. And,
intracellular total cholesterol and FFAs were significantly
reduced. Furthermore, StAR overexpression inhibited
mRNA expression and secretion of inflammatory factors
by blocking NFκB nuclear translocation. Finally, StAR
overexpression attenuated the reduction of NOFigure 7 The protective role of StAR in PA-induced endothelial dysfu
metabolism are greatly reduced following StAR overexpression. As a result,
overexpression, which maintains the homeostasis of lipids. Levels of mRNA
decreased after PA treatment, which is due to the blockade of NFκB nuclea
reduction of NO bioavailability induced by PA are compensated by StAR obioavailability induced by PA treatment via regulating the
p-Akt/p-eNOS/NO pathway.
An elevation of circulating FFAs is supposed to be
related to the onset and progression of endothelial
dysfunction [39,40], and associate with a number of
cardiovascular risk factors, including hypertension, dys-
lipidemia, and abnormal fibrinolysis. It has been noted
that FFAs may increase the production of multiple
cytokines in mononuclear cells by generation of reac-
tive oxygen species (ROS) and activation of the pro-
inflammatory NFκB pathway in human endothelial cells
[41,42]. In the present study, we used PA as one of the
major mediators to induce endothelial dysfunction by
activating inflammation and reducing NO biovailability.
When the endothelium in vessels is affected by risk fac-
tors, such as pro-inflammatory factors or hyperlipidemia,
it will be activated and secrete inflammatory factors.
Cell adhesion molecules including intercellular adhesion
molecule-1 (ICAM-1), vascular adhesion molecule-1
(VCAM-1) and E-selectin are the biomarkers of endo-
thelial activation [43]. As shown in our study, the mRNA
expression and secretion of inflammatory factors were
greatly increased after PA treatment in cultured rat
aortic endothelial cells, while the mRNA expression of
VCAM-1 was also upregulated significantly. However,
the extent of increase is reduced when StAR is over-
expressed by adenovirus infection. As shown by previous
studies, the transcription factor NFκB regulates the
expression of numerous genes including those related
to pro-inflammatory responses, such as L-1β, IL-6,
TNFα and VCAM-1, IL-1α [35,44]. We found that NFκB
translocation from cytosol to nucleus was blocked bynction. In rat aortic endothelial cells, the key genes involved in lipid
the cellular levels of cholesterol and FFAs are also reduced after StAR
expression and secretion of inflammatory factors were significantly
r translocation and activation after StAR overexpression. Moreover, the
verexpression.
Tian et al. Cardiovascular Diabetology 2012, 11:144 Page 11 of 12
http://www.cardiab.com/content/11/1/144StAR overexpression. Thus, StAR could attenuate inflam-
matory responses in endothelium via its blocking of
NFκB translocation.
There is strong clinical evidence that endothelial dys-
function contributes to the pathogenesis of cardiovascu-
lar disease and insulin resistance [45,46]. Endothelial cell
dysfunction is defined by a decrease in the bioavailability
of nitric oxide (NO), a critical regulator of vascular tone
[47]. Endothelial nitric oxide synthase (eNOS) serves as a
critical enzyme in producing NO. As shown in previous
studies, the pAkt/peNOS/NO pathway was inhibited by
PA treatment [19,20,46]. Our observations in this study
demonstrated that StAR overexpression in endothelial
cells attenuated the reduction of phosphorylation of Akt
and eNOS, as well as NO production. Previous studies
have shown an inverse correlation between StAR and
NO in the steiodogenic tissues [48,49], in which NO was
produced from activation of iNOS (also named NOS2).
However, in our study, we observed a direct correlation
between StAR and NO in vascular tissue, where NO is
produced from eNOS (named NOS3). This suggests that
StAR could take different roles in physiological process
at different location. As shown in previous reports, NO
production is regulated by a complicate network, includ-
ing interactions among CaM, Cavelion-1, BH4 and ROS
to regulate activation of eNOS (Ref ). Each step in the
network will affect the production of NO, and as a
result, StAR overexpression ameliorates the reduction
of NO production induced by PA treatment at a mild
degree. Our results using siRNAs to inhibit StAR expres-
sion confirmed a positive role for StAR in endothelial
dysfunction.
As already demonstrated in many investigations, lipids
overload is a major risk factor for endothelial dysfunc-
tion. Our data obtained in the present study indicate that
StAR inhibits lipid synthesis and uptake, PA-induced
inflammation, and reduction in NO bioavailability in
aortic endothelial cells. The inhibitor of FAS and HMGR
could also ameliorate the inflammatory response induced
by PA in RAECs. Taken together, the role of StAR over-
expression in inhibiting inflammatory response and NO
bioavailability in the cellular model of endothelial dys-
function might result from decreased lipid levels in
RAECs.
Conclusions
In conclusion, the present study demonstrated that StAR
overexpression in RAECs decreased intracellular total
cholesterol and FFAs levels. Furthermore, StAR overex-
pression inhibited PA-induced inflammatory response,
and attenuated reduction in NO bioavailability. Taken
together, these results indicate that StAR plays a protect-
ive role in PA-induced endothelial dysfunction via regu-
lating intracellular lipid metabolism.Abbreviations
NO: Nitric oxide; StAR: Steroidogenic acute regulatory protein; FFA: Free fatty
acid; RAECs: Rat aortic endothelial cells; PA: Palmitic acid.
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